Bioactive Small Molecules
Cayman Chemical ANTIBODY GW 806742X 25mg
An inhibitor of necroptosis; binds to Mlkl (Kd = 9.3 µM for the mouse protein) and decreases necroptosis induced by TNF-α, a Smac mimetic, and Q-VD-OPH in isolated mouse dermal fibroblasts at 500 nM; an inhibitor of VEGFR2 (IC50 = 2 nM); decreases VEGF-induced proliferation of HUVECs (IC50 = 5 nM); inhibits mammosphere formation by, reduces the number of extracellular actin fibers extruding from, and decreases intracellular IL-1β levels in, MDA-MB-231 cancer cells at 10 µM
Cayman Chemical Bacopaside II 5MG
A triterpene glycoside; decreases hydrogen peroxide-induced intracellular ROS production and cell death in N2a neuroblastoma cells at 0.4 mg/ml; decreases immobility time in the forced swim and tail suspension tests in mice, indicating anti-depressant like activity, at 50 mg/kg; decreases migration and tube formation in 2H11 and 3B11 cells, as well as HUVECs when used at greater than 15 µM; inhibits the growth of MDA-MB-231, SHG-44, HCT8, A549, and PC3M cancer cells (IC50s = 32.4, 36.9, 40.3, 44.4, and 45.4 µM, respectively)
Cayman Chemical ANTIBODY m-206 5mg
A STAT3 inhibitor (IC50 = 1.16 µM); inhibits G-CSF-induced STAT3 phosphorylation in HL-60, Kasumi-1, and MOLM-13 AML cells (IC50s = 0.8, 1.9, and 1.1 µM, respectively); slows disease progression and improves survival in an AML mouse xenograft model (30 mg/kg per day)
Medchemexpress LLC Adenosine amine congener (ADAC) | 96760-69-9 | 99.2% | 100 MG
Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist known for its ability to ameliorate noise- and cisplatin-induced cochlear injury. It also exhibits neuroprotective effects, protecting sensory hair cells and reducing oxidative stress.
- Selective A1 adenosine receptor agonist
- Ameliorates noise- and cisplatin-induced cochlear injury
- Provides neuroprotective effects
- Reduces oxidative stress in the noise-exposed cochlea
- Protects sensory hair cells and reduces cisplatin-induced apoptosis
- Inhibits glutamate release and voltage-gated Ca2+ channels for otoprotection
Apexbio Technology LLC GNE-617 hydrochloride 10mg
GNE-617 hydrochloride is a small-molecule inhibitor targeting nicotinamide phosphoribosyltransferase (NAMPT) It is designed to inhibit NAMPT thereby disrupting NAD biosynthesis in cells GNE-617 hydrochloride exerts its biological activity primarily by competitively inhibiting the NAMPT substrate leading to decreased intracellular NAD levels In cell-based studies GNE-617 hydrochloride demonstrates nanomolar-range antiproliferative activity in multiple cancer cell lines including glioblastoma (U251) fibrosarcoma (HT1080) prostate carcinoma (PC3) pancreatic adenocarcinoma (MiaPaCa2) and colon carcinoma (HCT116) Based on these pharmacological properties GNE-617 hydrochloride holds research potential in the investigation of NAMPT-dependent cancer biology and therapeutic applications
Cayman Chemical ColchIcosIde 5mg
A glycoside form of 3-demethylcolchicine; does not displace [3H]-colchicine from rat brain tubulin in vitro at 25 μM; increases CYP2C9 and CYP2E1 levels in primary human hepatocytes at 1 and 10 μM
Cayman Chemical ANTIBODY CynIn 100mg
An organic dye composed of two N-heterocycles surrounding a polymethine
Cayman Chemical 3-hydroxy TrIdecnoIc AcId 5mg
A fatty acid found in bacteria; used as an internal standard to detect markers of microorganisms in complex samples
Medchemexpress LLC BMS-202 | 1675203-84-5 | 99.4% | 419.52 | 50 MG
BMS-202 is a potent, nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. It binds to PD-L1, blocking human PD-1/PD-L1 interaction, and exhibits antitumor activity.
- Potent and nonpeptidic PD-1/PD-L1 complex inhibitor
- Binds to PD-L1 and blocks human PD-1/PD-L1 interaction
- Exhibits antitumor activity
- Soluble in various in vitro and in vivo solutions
- Stable under recommended storage conditions
- Cited in numerous scientific publications
Cayman Chemical ANTIBODY GDC-0575 25mg
A Chk1 inhibitor (IC50 = 1.2 nM); >30-fold selective for Chk1 over a panel of more than 450 wild-type and mutant kinases; enhances cytarabine-induced apoptosis in HL-60, KG-1, U937, and ML-1 AML cells; nearly completely eliminates tumor burden in AML PDX mouse models at 7.5 mg/kg in combination with cytarabine
Medchemexpress LLC Tinengotinib | 2230490-29-4 | >98.0% | 394.86 g/mol | C20H19ClN6O | 5 MG
Tinengotinib is an orally active small-molecule multi-kinase inhibitor used in preclinical oncology research. It potently inhibits Aurora A/B and FGFR family kinases, and also shows activity against VEGFRs, JAK1/2, and CSF1R. By blocking Aurora kinase-mediated cell cycle progression, it induces G2/M arrest, promotes apoptosis, and inhibits proliferation and angiogenesis. It is applied in studies of triple-negative breast cancer, gallbladder cancer, and tumor immune microenvironment. For research use only.
- Orally active small-molecule kinase inhibitor.
- Potent multi-kinase activity including Aurora A/B and FGFR1-3.
- Induces G2/M cell cycle arrest and apoptosis.
- Demonstrates anti-proliferative and anti-angiogenic effects in preclinical models.
- Available as solid and DMSO solution formats for flexible dosing.
- Reported purity >98% and molecular weight 394.86 g/mol.
- Intended for preclinical research use only.
Medchemexpress LLC Bms 986020 | 1257213-50-5 | MFCD30489743 | >=95.0% | 482.5 g/mol | C29H26N2O5 | 50 MG
BMS-986020 is a small-molecule, selective lysophosphatidic acid receptor 1 (LPA1) antagonist used as a research reagent in studies of pulmonary fibrosis and LPA1 signaling. It is supplied as a solid, white to yellow powder (CAS 1257213-50-5) with molecular formula C29H26N2O5 and molecular weight 482.53 g/mol.
- Selective LPA1 antagonist suitable for receptor pharmacology studies.
- Well-characterized chemical identity with published CAS, formula, and molecular weight.
- Supplied as a solid powder appropriate for in vitro and preclinical assays.
- Typical vendor-reported purity ≥95% (may vary by supplier; check lot certificate of analysis).
- Recommended storage refrigerated or at -20 °C; follow supplier SDS for handling and safety.
Medchemexpress LLC Glycerol (standard) | 56-81-5 | 98.9% | 100 MG
Glycerol (Standard) is the analytical standard of Glycerol, intended for research and analytical applications. It is used in sample preparation and gel formation for polyacrylamide gel electrophoresis. This product, an analytical standard, serves as a reference standard with a supplied assay and is commonly employed in qualitative, quantitative, and methodological research experiments such as HPLC, GC, and MS.
- Used as an analytical standard.
- Suitable for research and analytical applications.
- Employed in sample preparation and gel formation for polyacrylamide gel electrophoresis.
- Commonly used in qualitative, quantitative, and methodological research experiments including HPLC, GC, and MS.
Medchemexpress LLC MrgprX2 antagonist-2 | 2642346-30-1 | 99.2% | C17H16F5N3O3 | 50 MG
MrgprX2 antagonist-2 is an MrgprX2 antagonist, extracted from patent WO2021092262A1, example E163. It is designed for the research of inflammatory disorders of the skin. This product is for research use only and intended for experienced personnel in appropriately equipped and authorized facilities.
- Targets MrgprX2
- Expressed in sensory neurons, mast cells, and keratinocytes
- Activation of MRGPRX2 leads to mast cell degranulation
- Stable under recommended storage conditions
- Solid appearance
- Light yellow to yellow color
- Store at 4°C, protected from light
- In solvent, store at -80°C for 6 months or -20°C for 1 month, protected from light
Cayman Chemical Oclactnb 5mg
A JAK family kinase inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively); selective for JAK kinases over a panel of 38 additional kinases at 1 μM; inhibits LPS-induced increases in IL-12 and TNF-α levels in murine BMDCs in a concentration-dependent manner; topical administration reduces scratching behavior and EAr edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in EAr skin, in a mouse model of TDI-induced allergic dermatitis at 0.1, 0.25, and 0.5%